GGrantIndex
← Search

Cancer Center Support Grant

$3,677,096P30FY2006CANIH

University Of Colorado Denver, Aurora CO

Investigators

Linked publications, trials & patents

Paper 39763739Paper 39737640Paper 39726772Paper 39711559Paper 39711135Paper 39684443Paper 39677775Paper 39677720Paper 39677022Paper 39671500Paper 39671496Paper 39630148Paper 39609428Paper 39604567Paper 39603869Paper 39574899Paper 39564580Paper 39554114Paper 39436696Paper 39400608Paper 39384405Paper 39342284Paper 39321266Paper 39311710Paper 39282307Paper 39266537Paper 39264810Paper 39215796Paper 39201277Paper 39191549Paper 39147413Paper 39139560Paper 39136655Paper 39120971Paper 39091762Trial NCT05073848Trial NCT05053737Trial NCT05006040Trial NCT04993859Trial NCT04988490Trial NCT04973007Trial NCT04963283Trial NCT04940468Trial NCT04925193Trial NCT04922112Trial NCT04916990Trial NCT04882111Trial NCT04866758Trial NCT04863092Trial NCT04634110Trial NCT04611022Trial NCT04565457Trial NCT04558138Trial NCT04544592Trial NCT04541407Trial NCT04535102Trial NCT04520867Trial NCT04486573Trial NCT04471363Trial NCT04408092Trial NCT04305366Trial NCT04300478Trial NCT04294693Trial NCT04208243Trial NCT04092803Trial NCT04091867Trial NCT04066218Trial NCT04042935Trial NCT04035408Trial NCT04028167Trial NCT04028063Trial NCT04001101Trial NCT03995082Trial NCT03976193Trial NCT03970226Trial NCT03958565Trial NCT03900793Trial NCT03891654Trial NCT03881098Trial NCT03781154Trial NCT03734653Trial NCT03617679Trial NCT03325634Trial NCT01886859Trial NCT01426334Trial NCT01232829Trial NCT00778167Patent 9434994Patent 8734778Patent 8715649Patent 8343502Patent 8337830Patent 8221763Patent 8153136Patent 8067559Patent 7910315Patent 7595060Patent 7563447Patent 7465454Patent 7083787

Abstract

DESCRIPTION (provided by applicant): The University of Colorado Cancer Center (UCCC) is the only NCI-designated comprehensive Cancer Center in the Rocky Mountain region - an area with a population of approximately eight million people. The goals are to reduce the cancer burden by: 1) conducting coordinated and interdisciplinary basic, clinical, translation, prevention and control, population, and educational research, 2) providing citizens of Colorado and the Rocky Mountain region with state-of-the art programs in cancer research, therapy, early detection, prevention and control, and 3) providing cancer education at all levels from students to the public sector. There are 271 full and 110 associate members who participate in one or more of the UCCC's eight programs including Cancer Cell Biology, Molecular and Structural Biology, Immunology and Immunotherapy, Hormone Related Malignancies, Tobacco Related Malignancies, Developmental Therapeutics, Carcinogenesis and Chemoprevention, and Clinical and Community Cancer Prevention and Control. Over the past five years, the NCI sponsored research portfolio has nearly doubled from $21 million to $39.7 million, excluding the CCSG. This was accomplished largely through the successful funding of major new collaborative NCI grants and contracts totaling more than $7 million annually and through the recruitment of 100 new members who hold more than $14 million in NCI grant support. Over the past five years, the number of subjects accrued to clinical trials and the number of outpatient visits have also doubled. The Cancer Center is a "matrix" Cancer Center within the University of Colorado Denver and Health Sciences Center and we are applying as a consortium with members from the University of Colorado at Boulder campus, the AMC Cancer Research Center, the National Jewish Medical and Research Center, and the Colorado State University campuses. These consortium members strengthen and broaden cancer research activities. Member research is supported by 15 shared core resources, of which the Informatics shared resource and the Structural Biology shared resource are new. Major new services and equipment were added to most of the shared resources. Center members also benefit from the Development activities of the Cancer Center that bring new recruitments, pilot projects and shared facilities. Planning and evaluation efforts have allowed our on-going move to the new Fitzsimons campus to provide state-of-the art facilities and increased collaborations. The completion of the new campus will allow continued growth over the next five years.

View original record on NIH RePORTER →